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INTRODUCTION
1INTRODUCTION
Acute Kidney injury(AKI) is a clinical syndrome characterized by
the rapid fall in glomerular filtration rate (GFR)occurring over hours to
days resulting in the accumulation of nitrogenous waste products  as
well as deregulation of fluids electrolytes and acid base balance(1).
Although the precise occurrence of AKI is difficult to estimate, hospital
based studies estimate its incidence to 3-7% (2,3) The incidence of AKI
is increasing from 18 per 100000 from 1980 to 365 per 100000 in
2005(4). AKI causes significant morbidity and short term mortality of
50%(5,6,7). The discovery of Urinary and Serum Biomarkers has made
the identification of AKI in its preclinical phase thereby allowing the
clinicians to aggressively intervene to prevent further damage. The
burden of AKI lies not only in in-hospital mortality and morbidity, but
also in its long term outcome of progression to Chronic Kidney Disease.
A traditional concept of regarding renal outcome after an episode of
AKI that 5%experience no recovery, 5% manifest progressive renal
dysfunction has changed considerably now. Recent studies have shown
10-40% of dialysis requiring AKI remain dialysis dependent. Also it
increases the risk of developing progressive CKD by 28 folds (8). Time
has evolved now to view AKI as part of AKI-CKD syndrome were AKI
brings out subtle renal abnormalities to the fore. To emphasis the above
2mentioned points this study was done to analyze the characteristics and
the short term outcome of severe AKI (AKIN stage III) patients
admitted in Govt. Stanley Medical College and Hospital.
AIM
3AIM
To analyze the characteristics and short term (three month)
outcome in Acute Kidney Injury (Acute Kidney Injury Network
Stage III).
REVIEW OF
LITERATURE
4REVIEW OF LITERATURE
Although more than 30 definitions are available for the acute
kidney Injury the following definition holds good for the better
understanding of AKI
“It is a rapid decline in renal function over 48 hours as
demonstrated by an increase in Serum Creatinine of more than 0.3mg/dl
or more than 50% increase in base line serum creatinine or the
development  of Oliguria”(9).
AKI is a clinical syndrome of varying manifestations from
completely asymptomatic to severe uremic symptoms due to the
accumulation of nitrogenous waste products. No doubt it causes
considerable morbidity and mortality to the patients. The burden of AKI
not only mention the in-hospital mortality and morbidity but also with
the long term outcome of dialysis dependency, risk of developing
progressive chronic kidney disease and all cause of death.(5,6,7,8,10).
EPIDEMIOLOGY & CLASIFICATION:
The exact occurrence of AKI in the community and in hospital is
not clear due to the application of varying criteria and definitions to
diagnose AKI. To bring about uniformity and reproducibility of defining
5AKI, Acute dialysis quality initiative group (ADOQI) in 2002 first
proposed the consensus definition for AKI. It was named as RIFILE
criteria with the classification scheme consist of three strata for its
diagnosis (R, I, F) and two outcome stages (L&E) (11). The first strata
give the highest sensitivity of diagnosing AKI and the third strata, the
highest specificity.
Recently AKIN (Acute Kidney Injury Network) has come up with
the modifications of RIFILE criteria which comprise R, I&F criteria
with the addition of increase in serum creatinine of ? 0.3 mg/dl to the
RISK ® class(12).
6Small but important difference exists between the two
classifications.
1. The time constraint of  48 hours for the diagnosis of AKI is
required in AKIN criteria in contrary to RIFLE criteria of 7 days
2. GFR is taken into consideration for RIFLE criteria.
3. RIFLE classes I & E are not reported in AKIN stages
4. Both the systems utilize serum creatinine and urine output
criteria. Only one criteria has to be meet to qualify for the given
class and stage of AKI.
5. Dialysis requiring AKI is placed in AKIN stage III irrespective of
Serum Creatinine or Urinary abnormalities.
7LIMITATION OF BOTH THE SYSTEMS
1. Unable establish the concordance between serum creatinine
and urine output even with mortality risk.
2. Poor correlation between GFR and AKI stages.
3. Excessive reliance of base line creatinine which in many times
are unavailable.
4. Relative changes in Sr. creatinine to the time required to attain
the fixed percentage depend upon baseline renal function.
After the advent of these two major systems, the physician
community has gone a bit closer to precisely estimate the incidents of
AKI. Recent estimation showed that 3-7% of hospitalized patients
develop AKI as to 25-30% of the ICU patients (2,3). Requirement of
RRT is 5-6%. As per national hospital discharge survey in the US, there
were increased hospital discharges from dialysis requiring AKI, from
18/100000 in 1980 to 365 /100000 in 2005(13). Also dialysis requiring
AKI are also on the rise with the increase from 322.7-522.4 per 100000
person years from 1996 – 2003(14).
8ETIOLOGY OF AKI
It is traditionally classified as Pre renal, Intrinsic renal and Post
renal AKI for the diagnostic approach. Even though there maybe
overlap among the components.
PRE RENAL AKI:
It is the most common cause of AKI accounting for 40-55%. It is
the easily reversible form of AKI resulting from hypo perfusion of the
kidneys resulting from decreased in effective arterial volume. Although
reversible, prolonged hypo perfusion to kidneys may result in
parenchymal damage and eventually resulting in intrinsic AKI.
Causes of Pre renal AKI:
Volume depletion:
? Renal losses - Diuretics, polyuria
? GI losses - Vomiting, diarrhea
? Cutaneous losses - Burns, Stevens-Johnson syndrome
? Hemorrhage
? Pancreatitis
9Decreased cardiac output :
? Heart failure
? Pulmonary embolus
? Acute myocardial infarction
? Severe valvular disease
Systemic vasodilatation:
? Sepsis
? Anaphylaxis
? Anesthetics
? Drug overdose
Afferent arteriolar vasoconstriction:
? Hypercalcemia
?  NSAIDs, amphotericin B, calcineurin inhibitors, nor epinephrine,
radio contrast agents
? Hepato -renal syndrome
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Diseases that decrease effective arterial blood volume:
? Hypovolemia
? Heart failure
? Liver failure
? Sepsis
Hypovolemia results in the activation of baroreceptors and
osmotic center in the brain leading to the production and release of
catecholamine and ADH respectively. Increase in the intra renal activity
of angiotensin II secondary to hypovolemia to maintain GFR becomes
maladaptive when the volume depletion prolongs (15). Local myogenic
reflex to maintain GFR by selectively dilating afferent arteriole fails
when the mean systemic arteriolar blood pressure falls below 75-
80mmHg. Although these compensatory mechanisms act in concert to
prevent AKI they both are overcome when the state of  hypo perfusion
prolongs, eventually resulting in pre renal AKI. Pre renal AKI in turn
pre disposes  the patient to Acute Tubular Injury (Intrinsic AKI).
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INTRINSIC AKI:
The causes of the intrinsic AKI can be divided based on the
various renal components viz., large vessels, micro vasculature, tubule
interstitium and glomeruli. It is the second most common cause of AKI.
Etiology of Intrinsic renal AKI:
? Renal artery obstruction - Thrombosis, emboli, dissection,
vasculides
? Renal vein obstruction - Thrombosis
? Microangiopathy - TTP, HUS, disseminated intravascular
coagulation (DIC), preeclampsia
? Malignant hypertension
? Scleroderma renal crisis
? Transplant rejection
? Atheroembolic disease
Glomerular causes:
Anti-glomerular basement membrane (GBM) disease -
Goodpasture syndrome or renal limited disease
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? ANCA-–associated glomerulonephritis (ANCA-associated
glomerulonephritis) - Wegener granulomatosis, Churg-Strauss
syndrome, microscopic polyangiitis
? Immune complex glomerulonephritis - Lupus, post infectious
glomerulonephritis, cryoglobulinemia, primary membrano-
proliferative glomerulonephritis.
Tubular etiologies:
?  Rhabdomyolysis, intravascular hemolysis
? Tumor lysis syndrome, seizures, ethylene glycol poisoning,
megadose vitamin C, acyclovir, indinavir, methotrexate
?  Aminoglycosides, lithium, amphotericin B, pentamidine,
cisplatin, ifosfamide, radiocontrast agent
Interstitial nephritis causes include the following:
Penicillin, cephalosporin, NSAIDs, proton-pump inhibitors,
allopurinol, Rifampin, indinavir, mesalamine, sulfonamides
 Pyelonephritis, viral nephritides
Systemic disease - Sjögren syndrome, sarcoid, lupus, lymphoma
leukemia, TINU Syndrome.
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POST RENAL AKI:
It is caused by the obstruction to either ureter, bladder or urethra .
It accounts for < 5% of AKI initially increased intra tubular pressure is
compensated by the decrease in afferent renal arteriolar vasodilatation
so as to maintain single nephron GFR (SNGFR). Later after 24 SNGFR
falls rapidly as a result of progressive rise in intra tubular pressure
unattended by the static afferent arteriolar tone.
Causes of post - renal AKI:
? Stone disease
? Stricture
? Intraluminal, Extraluminal, or intramural tumors
? Thrombosis or compressive hematoma
? Fibrosis
PATHOPHYSIOLOGY OFAKI:
The understanding of the pathophysiology of renal diseases is
well characterized by the animal models. Ideal models should have
reproducibility, clinical relevance, therapeutic value, possibility of study
of mechanism to have control over extrinsic factors and isolation of
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single variables.  Unfortunately none stood because AKI has multi
factorial etiology and most of the humans have premorbid illness. The
hypo perfusion / cardiac arrest model for ischemic AKI and cecal
ligation and puncture (CLP) for septic AKI are considered to be closely
associated with human counterpart (16,17,18,19). Although all segments
of nephron can undergo injury during ischemic insult, epithelial cells
especially of S3 segment are the most vulnerable,(20) followed by
endothelial cells(21). Proximal tubular cell injury results in drop in GFR
through afferent arteriolar vasoconstriction primarily mediated through
proximal tubular obstruction and tubule glomerular feedback (22,23).
Even though proximal epithelial cells burn much of the injury in the
early phase, there occurs a cross talk between the epithelial and
endothelial cells mediating final insults like vasoconstriction, tubular
cell apoptosis, necrosis, inflammation. Sub lethal injury to epithelial
cells lead to actin cytoskeleton disruption causing detachment of
microvilli, membrane bound extra cellular vesicles or blebs (24), loss of
basolateral tight junction(25), redistribution of Na / K ATPase and
integrins to apical location(26) and cast formation. Lethal injury
produces apoptosis and necrosis of epithelial cells. Number of potent
mediators of inflammation like TNF-?, IL-6 , IL-8 ,MCP, TGF-? are
secreted by injured proximal tubular epithelial cells(27) as do TLR-2,
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C5&C4(28), causing parenchyma inflammation and subsequent damage.
Endothelial dysfunction causes continued ischemic renal insult; hence it
is rightly termed as the Extension phase of AKI. With ischemia, renal
vascular bed shows vasoconstriction probably as the result of imbalance
between eNOS and iNOS (29) followed by the disruption in actin
cytoskeleton causing endothelial swelling and increased permeability
(30), activation of coagulation cascade, consumption of protein C, and
thrombomodulin (31). Endothelial dysfunction also causes inflammation
through leukocyte recruitment (32), erythrocyte trapping and roulex
formation (33). Due to the better understanding of the pathogenesis in
AKI, various experimental therapies were tried in animal models to halt
its progression  including CD133+ progenitor / stem cells, mesenchymal
stem cells, VEGF, endothelial progenitor cells (CD 34, 133, VEGF
receptor 2)
CLINICAL ASSESMENT & DIAGNOSIS:
Pre renal AKI should be suspected if there is evidence of intra
vascular volume depletion like sense of thirst, orthostatic hypotension
and tachycardia (postural drop in diastolic BP >10 mmHg and
tachycardia > 10 beats/ min), decreased jugular venous pressure,
diminished skin turgor, absence of auxiliary sweat. Volume
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unresponsive pre renal AKI may be suspected in patients with CCF,
liver disease, Nephrotic syndrome with the evidence of pedal edema
pulmonary congestion, cardiomegaly, elevated JVP. Intrinsic renal AKI
should suspected in euvolemic renal failure with varying symptoms with
respect to renal compartments affected. Flank pain, nausea, Hematuria,
cutaneous nodules, lividoreticularis, absent peripheral pulses,
cholesterol plaques in the retina. Nephrotoxic ATN can be diagnosed
with reviewing of pharmacy prescriptions, radio contrast exposure and
native medicine intake. Pigment ATN should be suspected in the setting
of rhabdomyolysis and haemolysis. Acute interstitial nephritis is evident
from the recent exposure of drugs, maculopapular rashes, arthralgia and
Eosinophilia. Primary and secondary glomerular diseases as a cause of
AKI should be entertained in the presence of Glomerular Haematuria,
proteinuria along with or without the features of extra renal features like
rashes arthralgia, neuropathies, fever, etc., Post renal AKI usually
present with anuric renal failure but a pattern of fluctuating urine output
is not unusual. Presence of suprapubic flank pain, palpable bladder by
abdominal examination and enlarged prostrate by pre rectal examination
should point towards its diagnosis.
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LABORATORY INVESTIGATIONS:
Urine analysis has always been a strong point in diagnosing
various etiologies of AKI. Presence of normal or few RBC and WBC in
urine suggest Pre renal and Post renal AKI. Presence of granular casts
suggests acute tubular necrosis, RBC casts in vasculides,
Glomerulonephritis and WBC casts in interstitial nephritis and acute
pyelonephritis. Eosinophilia usually suggests atheroembolic renal
disease and acute interstitial nephritis. Crystalluria occurs in drugs like
sulfonamides, acyclovir, indinavir, acute urate nephropathy and radio
contrast exposure. The application of FeNa to distinguish pre renal and
intrinsic renal AKI has gone to disrepute in view of overlapping values
in both these conditions. Urine, uric acid / creatinine ratio> 1 suggest
tumor lysis syndrome or acute urate nephropathy. Radiological imaging
is most important in diagnosing post renal AKI which includes plain
radiography, ultrasonogram, Computed Tomography, MRI & antegrade
and retrograde pyelography.
URINARY BIOMARKERS:
Biomarker is defined as a characteristic that is objectively
measured and evaluated as an indicator of normal biological processes,
18
pathogenic processes or pharmacological responses to therapeutic
interventions (33).
The advent of biomarkers has made the diagnosis of AKI at the
damage stage of the conceptual model. Urinary biomarkers that are
detected in the AKI patients are either specifically produced by the
injured proximal tubular cells or due to the failure of proximal tubular
cells to absorb the specific filtered proteins. Numerous novel biomarkers
are being discovered for clinical application in AKI detection, especially
post operative AKI.
The following are significances are attributed to the urinary
biomarkers:
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1. Predicts AKI much earlier than elevation of serum creatinine
(34,35,36).
2. Intensity of elevation is correlated with the need for dialysis,
death and duration of hospital stay(37,38)
3. Detection in the urine till the renal recovery is complete.
The list of tubular injury biomarkers is increasing as time rolls on.
The list includes ?1 Microglobulin, ?2- Microglobulin, glutathione, S-
transferase, IL-18, KIM-1, liver type fatty acid binding protein, netrin-1,
NGAL, NAG and Urinary cystatin-C. Of these, KIM-1, NGAL, NAG
has more sensitivity and specificity (80-95%) (34).
COMPLICATION OF AKI :
 It includes hyperkalemia, metabolic acidosis, volume overload,
cardiac complications like arrhythmia, myocardial infarction and
pulmonary embolism, Anemia, Platelet dysfunction, Clotting factor
abnormalities, Infections (most common and serious complication) (39),
Pericarditis, Uremic encephalopathy, Malnutrition and GI bleed.
Recovery phase of AKI is complicated by volume depletion,
hypernatremia, hypokalemia, hypomagnesaemia, hypophosphatemia and
hypocalcaemia.
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MANAGEMENT:
GENERAL PRINCIPLES:
1. It includes early goal targeted volume replacement to pre defined
hemodynamic targets (MAP >65mmHg), CVP-10-12mmHg,
target urine output more than 0.5 ml/kg/hour, central venous
oxygen saturation >70% with the usage of combined crystalloids,
blood transfusion and vasopressors (40).
2. Intensive blood sugar control of 80-110 mg/dl using insulin
therapy (41).
3. Avoidance of nephrotoxic agents and drugs that interfere with the
compensatory mechanisms during renal hypo perfusion like
amino glycosides, diuretics, NSAIDS, ACEI and ARBs(42).
Medical therapy with low dose dopamine, fenoldopam, ANP,
mannitol & loop diuretics are not effective in reducing the need for
replacement therapy or mortality (43,44,45,46,47 ).
RENAL REPLACEMENT THERAPY (RRT):
Apart from the traditional and absolute indications for renal
replacement therapy in AKI much debate has already underway
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regarding the timing of initiation of dialysis, modality and frequency of
RRT. RRT in AKI includes intermittent hemodialysis (IHD),
Continuous renal replacement therapy (CRRT), Hybrid therapies and
Peritoneal dialysis. Single randomized controlled trial regarding the
early initiation of RRT in AKI did not show any benefit in mortality or
early recovery (48) . Two randomized controlled trials comparing CRRT
and IHD, showed no differences in in-hospital and 30 days mortality
rate (49,50). The VA / NIH and RENAAL trials to assess the outcome
of more intensive dialysis ( IHD 6 times / week and CRRT
35ml/kg/hour) over less intensive arm (3 times a week and CRRT
20ml/kg/hour) did not show any significant benefit for more intensive
arm(51,52). Peritoneal dialysis (PD) is always being an option for
patients who don’t have access for IHD or CRRT with studies showing
lesser efficacy in terms of metabolic control for PD over others (53),
although a study from Brazil has showed equal efficacy against its
counter parts(54).
OUTCOMES OF AKI
The short term mortality in intrinsic AKI is around 50 %
(5,6,39,55). Although this figure may vary depending upon various
etiologies, septic AKI causes 60-90% mortality and obstetric AKI 15%
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(5,56,57). The overall 60 days and 90 days mortality rates were 52.6%
and 44.7% respectively as per VA/NIH and RENAAL trials. The
dialysis dependency rates following AKI varies from 10-40%
(51,52,58). Ishani et al, recently reported that AKI was independently
associated with three fold increased risk of developing ESRD (59). The
long term five year follow-up study by Schiffl and Fischer enrolling 425
patients treated with RRT found that 43% of patients had partial renal
recovery fulfilling stage 2-4 CKD (60). After one year, 27% had
meaningful improvements with 8.2% fully recovering, 10% worsened
renal function at five years. The prevalence of CKD among survivors
was 14% with only 2% of survivors reached ESRD at five years.
The mechanism of progression of AKI chronic kidney disease
could be explained by remnant kidney animal model where by the
nephron loss from AKI result in hyper filtration, intra renal
hypertension, tubular hypertrophy, attending arteriosclerosis, tubulo
interstitial fibrosis and eventually glomerulosclerosis(62). The trigger of
inflammation by proximal tubular cell injury leads to interstitial cell
infiltration initially by neutrophils and later on by the monocytes –
lymphocytes which in turn mediates interstitial fibrosis through the
activation of cytokines like TGF-?, IL6, TNF ?, MCP1, IL1? (27) . The
endothelial injury contributes to the maintenance phase of AKI. The
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vascular restorative capacity after AKI is decreased leading to
significant decrease in blood vessel density (around 30-50% of normal)
known as vascular dropouts (61). The reason for the vascular dropouts
include ischemia induced inhibition of vascular endothelial growth
factor (VEGF) and the induction of ADAMTS1 (62, 63). This reduction
of micro vascular density activates the hypoxia induced pathways
leading to progressive inflammation and downstream fibrosis. This
mechanism of deficient VEGF induced vascular dropouts ultimately
dictates the progression of CKD. This has made to employ VEGF as a
treatment to prevent the progression to CKD. In experimental models
this compound has ameliorated vascular dropouts if administrated in the
immediate post injury period (64).
The traditional concept of AKI being a benign disease with only
5% progresses to CKD has been changed with the advent of wealth of
information supporting its high rate of progression to CKD.
MATERIALS AND
METHODS
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MATERIALS & METHODS
STUDY DESIGN: A prospective analytical study.
STUDY DURATION: January 2012 to December 2012
SETTING: Government Stanley Medical College and Hospital,
Chennai.
PARTICIPATING DEPARTMENTS: Departments of Nephrology,
General medicine, General Surgery, Surgical Gastroenterology &
Intensive Medical Care Unit.
STUDY POPULATION:
Patients admitted or developed Acute Kidney injury with Serum
Creatinine ? 3.0 mg/dl and/or Anuria for 12 hours.
INCLUSION CRITERIA:
The patients who got admitted (or) developed AKI with Serum
Creatinine ? 3.0 mg/dl and/or anuria of ? 12 hours.
EXCLUSION CRITERIA
AKIN I & II AKI, Preexisting Systemic hypertension, Diabetes
mellitus, Previous Renal disease, Decompensated liver disease,
Obstructive uropathy.
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MATERIALS:
Complete blood count (which includes blood hemoglobin, total
and differential WBC count, platelets counts and erythrocyte
sedimentation rate (automated hematology analyzer)
1. Random blood sugar by – GOD-PAP method.
2. Blood urea –  GIDH method
3. Serum Creatinine  by Jaffe’s method
4. Serum sodium  by  Ion specific electrode
5. Serum potassium  by  ion specific electrode
6. Sr. Bilirubin by  Biuret method.
7. Sr. SGOT by IFCC method
8. Sr. SGPT by  IFCC method
   10. Sr. alkaline Phosphatase by IFCC method.
   11. Sr. Protein by Biuret method
    12. Sr. Albumin by BCH method
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    13. Urine analysis – dipstick and direct microscopy for formed
elements
     14. Spot urine Sodium by ion specific electrode.
     15. Spot urine Creatinine by Jaffe method.
           FeNa was calculated by the formula :
  Urine Na / Serum Na x Serum Creatinine/ Urine Creatinine
16. Spot Urine protein by
  Spot Urine PCR>0.3 was considered abnormal protein excretion.
     17. Serum C3 – Immunoturbidometry
18.Serum C4 -   Immunoturbidometry
 19.ANCA - Immunofluorescence assay with ethanol fixed
neutrophils.
20.ASO titre – Immunoturbidometry
21.Peripheral smear for malaria  parasite or Quantitative buffy coat
for P.Vivax.
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22.Microscopic slide agglutination test or IgM ELISA ( enzyme
linked Immunosorbant assay) for leptospirosis.
23Culture studies which include urine, sputum & blood
24.Ultrasonography of abdomen and pelvis.
25.Plain Xray chest and plain X ray KUB (kidney, ureter & bladder)
if required.
26.Renal biopsy was done with 18 Gauge, 20 cm BARD Biopty
gun. Two linear cores were taken. One of the cores was processed in
10% formalin for the purpose of light microscopy and the other with
Michelle’s solution for Immunofluorescence study. For the light
microscopy, the stains used were Eosin and Haematoxylin, Periodic
acid Schiff, Mason trichrome and silver methenamine.
Immunofluorescence study was done for IgG, IgM, IgA, C1q,
fibrinogen, kappa and lambda light chains.
27.Glomerular filtration rate was estimated using Cockcroft-Gault
equation.
eGFR ? 90ml/min was considered as normal renal function and
eGFR < 90 ml/min as abnormal.
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METHODOLOGY:
All patients who were admitted or developed Acute Kidney Injury
with serum Creatinine >3.0 mg/dl in any of the wards in Government
Stanley Hospital were identified. Patients were included based on strict
inclusion and exclusion criteria.
Patients clinical characteristics were studied including age, sex,
Oliguria/anuria, volume overload, hypotension, uremic symptoms like
encephalopathy, pericarditis etc., were studied. Lab parameters that were
taken into consideration were Hemoglobin, Presentation urea and
creatinine, Peak urea and creatinine during hospital stay, Presentation
and discharge urine analysis, Discharge urea and creatinine.
The patients were managed with RRT (Renal replacement therapy) if:
1. Volume overload features.
2. Hyperkalemia.
3. Uremic encephalopathy.
4. Uremic symptoms like pericarditis, bleeding diathesis.
5. Anuria >12 hrs or prolonged Oliguria.
6. Severe metabolic acidosis.
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Renal biopsy was done in patients with:
1. Unexplained AKI.
2. Active urinary sediments with glomerular haematuria or
proteinuria.
3. In case of suspected ATN, if renal function didn’t improve after
3 weeks.
The patients were discharged either at clinical recovery or after
stabilization of renal function.
The surviving AKI patients were followed up after 3 months for
thorough clinical examination and lab investigations which
included urine analysis, spot urine PCR, Blood urea, Serum
creatinine. GFR was estimated through cockgraft-gault formula.
 Renal biopsy was done only if there was proteinuria and/or
hematuria and/or renal dysfunction at the follow up.
The presence of either proteinuria or hematuria or renal
dysfunction at 3 months follow up was considered abnormal and these
patients were considered to have persistent renal damage and probably
chronic kidney disease. The outcome of AKI at 3 months was observed.
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The risk factors for the presence of proteinuria/hematuria/renal
dysfunction/overall abnormalities were studied.
DEFINITIONS :
? Old age was defined as age above 50 years.
? Anemia was defined as blood hemoglobin less than 11 gm/dl.
? Volume overload was defined as the presence of edema and/or
elevated JVP and/or hypertension and/or pulmonary edema.
? Proteinuria was defined as urine PCR >0.3.
? Hematuria was defined as dipstick positive for blood.
? Renal dysfunction was defined as the presence of   eGFR <90
ml/min.
? Overall urinary abnormalities were defined as the presence of
Proteinuria and/or hematuria and/or renal dysfunction.
STATISTICAL METHODS:
The Pearson chi square test was used for independent variables.
Sample T Test was used for the comparison of mean variables. Multiple
logistic regression analysis was done for multivariate analysis. All
analysis was done through SPS software version 17.0.
RESULTS
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RF / Cause n=96
Acute nephritic syndrome(3)
Acute pyelonephritis(1),
cardiorenal(1),
heavy metal ingestion(1)
Drug induced(6)
Post surgical(8)
Acute febrile illness(12)
Postpartum AKI (6)
Leptospirosis(6)
Acute pancreatitis (7) ANCA vasculitis(2)
Malaria(6)
Sepsis(15
Acute diarrheal disease(23) ,
RESULTS:
Overall 96 patients were enrolled in the study after thoroughly
executing inclusion and exclusion criteria’s. 60 were male ad 36 were
female. Male: Female ratio was 1:6:1.
Age of the patients varied between 14-66 years. Median age was
36 years. For the purpose of better statistical analysis, age more than 50
years was considered as old age. 29 patients constituting 30.2% belong
to this group.
CAUSES OF ACUTE KIDNEY INJURY
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At presentation Oliguria/ anuria was present in 68 patients
(70.83%). Volume overload state was present in 23 patients (23.95%).
Hypotension was found in 6 patients (6.25%). Anemia was present in 64
patients. The mean blood hemoglobin was 10.5 ± 2.29 g/dl. The mean
Serum Creatinine at presentation was 5.2±2.9 mg/dl. The mean peak
Serum Creatinine during hospital stay was 7.2±3.14 mg/dl.
The mean blood urea at presentation was 135 ± 66.75 mg/dl. The
peak blood urea during the course of hospitalization was 162 ± 60.8
mg/dl. Hyponatremia was present in 52 patients (54.1%). The mean
serum sodium level was 133 ±13.95 mEq/dl. Hyperkalemia was
detected in 12 patients (12.5%). The mean Serum potassium was 4.1 ±
1.03mEq/dl. Proteinuria was found in 49 patients (51.04%). Haematuria
was found in 55 patients (57.29%). The combined urinary abnormalities
(hematuria and / or proteinuria) were present in 70 patients contributing
to 72.91% of the patient population.
Distribution of Causes of AKIN III AKI
Renal Biopsy in AKIN III AKI
,
AKIN III AKI Causes n=96
ADD 24%, n= 23
Sepsis15.6%, n=15
Acute Febrile Illness 12.5%,
n= 12
Post Surgical 8.3%,n=8
Acute Pancreatitis 7.3%, n=7
Malaria 6.3%, n=6
Renal Biopsy Distribution n=46
ATN 24%
AIN 7.3%
ATN + AIN 6.3%
TMA 3.1%
Cast nephropathy 1%
Endocapillary Proliferative GN
3.1%
Crescentic GN  3.1%
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Renal Biopsy distribution:
Frequency Percent
Valid
Percent
Cumulative
Percent
Nil 50 52.1 52.1 52.1
ATN 21 21.9 21.9 74.0
AIN 7 7.3 7.3 81.3
ATN 2 2.1 2.1 83.3
TMA 3 3.1 3.1 86.5
Cast nephropathy 1 1.0 1.0 87.5
Endocapillary
GN
3 3.1 3.1 90.6
Crescentic GN 3 3.1 3.1 93.8
ATN+AIN 6 6.3 6.3 100.0
Total 96 100.0 100.0
63 out of 96 patients underwent Renal Replacement Therapy
(RRT) out of which 62 underwent intermittent Hemodialysis (IHD) and
1 had Peritoneal Dialysis (PD).
The indications for RRT were:
Volume overload – 46,
Uremic encephalopathy – 13,
Prolonged Oliguria / anuria – 4,
Hyperkalemia–12.
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Number of HD sessions varied between 2– 22. The mean number
HD sessions were 8 ± 3.14. All IHDs were done with double lumen
temporary catheters (14 cm, 13.5 Fr). Access vein used were internal
jugular vein in 60 patients (96.77%), two patients had right subclavian
vein (3.22%). The mean number of days of HD initiation from the days
of detection of Acute Kidney Injury was 3±2.29 days, with the range of
number of days varied from 1-11 days. Peritoneal Dialysis was done in
one patient with rigid temporary PD catheter. The lone patient received
60 cycles and recovered completely. 33 patients were managed
conservatively (34.37%).
The table comparing the characteristics of RRT and
conservative groups:
Characters RRT ( n=63)
Conservative
group(n=33)
P value
Age (yrs) 38.13±14.47 41.03±12.91 0.340
Hemoglobin(g/dl) 10.06±2.05 11.40±2.55 0.005
Oliguria / anuria 52 16 0.002
Mean presenting
Creatinine (mg/dl)
5.72±3.02 4.26±2.08 0.021
Mean peak
creatinine (mg/dl)
8.32±3.02 5.079±2.19 <0.001
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Mean presenting
urea(mg/dl)
143±63.25 121±71.74 0.021
Mean peak
urea(mg/dl)
175.79±51.17 134.58±68.93 0.001
Mean Serum Na+
(mEq/dl)
133.09±6.6 133.8±7.72 0.640
Mean Serum
K+(mEq/dl)
4.1±1.01 4±1.03 0.126
Discharge Serum
Creatinine
2.32±1.22 1.72±0.68 0.015
Discharge Urine
abnormalities
38 10 0.018
Mortality 3 3 0.694
Proteinuria at 3
months
11 1 0.72
Haematuria at 3
months
19 3 0.042
Renal dysfunction
at 3 months
17 2 0.031
Abnormal Renal
biopsy at 3
months
12 1 0.030
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Mortality occurred in 6 patients (6.25%) . All the 3 patients in the
conservative group were presented with multi organ dysfunction and
very sick.
At discharge, renal dysfunction defined as GFR < 90 ml/min by
Cockcroft- Gault formula was found in 70 patients (77.77%). Among
them mild to moderate Renal failure (GFR >30 ml/min) was found in 36
patients (51.42%). Severe renal failure (GFR ? 30ml/min) was found in
34 patients (48.57%). Mean Serum Creatinine at discharge was 2.11±1.1
mg/dl. Urinary abnormalities were present in 47 patients (48.95%). The
overall discharge abnormalities were found in 79patients (87.77%).
At follow up after 3 months of all the surviving patients normal
renal functions defined as GFR > 90 ml/min was presenting 72 patients
(66.66%). Renal dysfunction (GFR< 90 ml/min) was found in 18
patients (33.34%).
The breakup of patients with various ranges of GFR:
GFR 60-90 ml/min 9 (26.6%)
GFR 30-60 ml/min 2 (3.33%)
GFR < 30ml/min 7(30%)
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Among the group with GFR < 30 ml.min, 5 patients were in
Dialysis dependent Renal Failure and the other two were Dialysis
Independent. Isolated urinary abnormalities without renal dysfunction
were detected in 10 patients (16.66%). The overall follow up
abnormalities was found in 30 patients (33.33%). The follow up renal
biopsy were done in 19 among the 30 patients who fulfilled the criteria
of renal biopsy (Hematuria and/or proteinuria and/or Renal
dysfunction). Among the left out 11 patients, 5 patients were in Dialysis
dependent renal failure and the other 2 had severe renal failure with
smaller sized kidneys. Biopsy was deferred in them. The four patients
with overall abnormalities refused renal biopsy. Among them one had
renal dysfunction alone. The rest three patients had microhematuria
alone.
 The initial histopathology of dialysis requiring renal failure
patients were:
Cast Nephropathy -1
Thrombotic microangiopathy with acute cortical necrosis - 2
Crescentic glomerulonephritis  - 2
Acute interstitial nephritis  -1
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Biopsies of severe renal failure not required dialysis:
Endo capillary proliferative glomerulonephritis  -1
Thrombotic microangiopathy -1
The 19 follow up biopsies, 6 biopsies were categorized as normal
(LM and IF) the remaining 13 biopsies which showed abnormalities, 5
had interstitial inflammation characterized by lymphocytic infiltrates
involving  < 30% of the core, 1 had infiltrates of 30-50%. Interstitial
fibrosis involving <30% core was found in 3 patients (26.3%), 30-50%
in 2 (15.78%), >50% in 1 (10.52%). Membrano proliferation pattern
was found in 1, mesangial proliferation in 1, Glomerulosclerosis
involving 50% of glomeruli in one, patchy cortical necrosis in one and
hyaline arteriosclerosis in another.
All the patients who were overall normal at discharge were found
to by normal at follow up. All the 6 normal biopsies were associated
with isolated renal abnormalities, 1 with hematuria alone had mesangial
proliferation with IgM C3, mesangial deposits. All the patients who had
renal dysfunction had abnormal renal biopsies.
Follow up Renal Biopsy
No biopsy-71
Abnormal-13
Normal-6
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Specific renal biopsy breakup:
Biopsy at AKI
presentation
Follow up normal
Biopsy
Follow up
abnormal Biopsy
ATN(n=23) 2 2
AIN(n=7) 2 4
ATN/AIN(n=5) 2 3
TMA with cortical
necrosis (n=3)
0 2
Endocapillary
proliferation with
exudation(n=3)
0 2
In the ATN Group 19 had complete recovery (biopsy not done), 2
had normal biopsies and the remaining two had abnormal biopsies (focal
interstitial inflammation, tubular atrophy involving < 30%).
In the AIN group, 4 were abnormal (interstitial inflammation
< 30%) -2, 30-50% - 1, interstitial fibrosis 30- 50% in 2 patients,
 >50% in 1.
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In the combined ATN / AIN, 3 had abnormal biopsies with
interstitial inflammation with fibrosis involving < 30%.
Endocapillary GN on follow up showed membranoproliferative
pattern in 1, another one showed glomerulosclerosis involving > 50% of
glomeruli (66.66%).
At 3 months follow up, proteinuria was found in 12 patients
(13.3%)
Risk factors analysis for Proteinuria at the end of three months
follow-up:
Follow-up proteinuria Vs Sex
Sex Yes No Total P Value
Male 3(25.5%) 54(69.2%) 57
Female 9(27.3%) 24(72.7%) 33 0.003
Total 12(13.3%) 78(86.7%) 90
Follow-up proteinuria Vs Presentation Proteinuria
Yes No Total P Value
Yes 7(14.9%) 40(85.5%) 47
No 5(11.6%) 38(88.4%) 43 0.649
Total 12(13.3%) 78(86.7%) 90
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Follow-up proteinuria Vs Presentation Haematuria
Yes No Total P Value
Yes 11(21.2%) 41(78.8%) 52
No 1(2.6%) 37(97.4%) 38 0.011
Total 12(13.3%) 78(86.7%) 90
Follow-up proteinuria Vs Presentation Urine Abnormalities
Yes No Total P Value
Yes 1 22 23
No 11 56 67 0.114
Total 22 78 90
Follow-up proteinuria vs Management
Yes No Total P Value
Conservative 1 29 30
RRT 11 48 59 0.72
Total 0 1 1
Follow-up proteinuria Vs Discharge Urine abnormalities
Yes No Total P Value
Yes 12 35 47
No 0 43 43 <0.001
Total 12 78 90
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Follow-up proteinuria Vs Discharge GFR
GFR > 90 GFR ? 90 Total P Value
Yes 34(73.9%) 12(26.1%) 46
No 37(84.1%) 7(15.9%) 44 0.237
Total 71(78.9%) 19(21.1%) 90
Comparison of Mean values with Follow-up proteinuria:
Yes No P Value
Age 38.5±14.6 39.1±13.1 0.89
Hemoglobin 9.2±1.41 10.8±2.39 0.027
Presentation Sr.
Creatinine
6.117±3.05 5.226±2.94 0.335
Peak Sr.
Creatinine
7.5±2.06 7.2±3.3 0.776
Presentation
Urea
169.5±90.2 130±61.97 0.058
Peak Urea 194±71.16 156.27±57.3 0.043
Hemodialysis
from day of
detection
3.18±1.5 3.02±1.9 0.80
Discharge Sr.
Creatinine
3.25±1.24 1.99±0.97 0.001
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Multiple logistic regression analysis for proteinuria at follow-up:
Observed Predicted
Proteinuria
Percentage
Correct
Yes No
Step 1 Follow up
Proteinuria
Yes 9 3 75.0
No 1 77 98.7
Overall Percentage 95.6
a  The cutoff value is .500
B S.E. Wald df Sig.
95.0% C.I.for
EXP(B)
Lower Upper
AGE .072 .060 1.456 1 .228 .956 1.209
SEX .208 1.618 .017 1 .898 .052 29.325
HB 1.038 .695 2.234 1 .135 .724 11.015
PEAK
CREATININE
1.765 .808 4.769 1 .029 1.198 28.466
PRESENTATION
CREATININE
-.661 .443 2.225 1 .136 .217 1.231
PEAK  UREA -.088 .056 2.467 1 .116 .820 1.022
PRESENTATION
UREA
.023 .034 .470 1 .493 .958 1.093
PRESENTATION
URINE
ABNORMALITIES
3.681 2.394 2.364 1 .124 .364 4326.865
DISCHARGE
CREATININE
1.138 1.114 1.043 1 .307 .351 27.721
DISCHARGE
UREA
-.128 .064 3.992 1 .046 .775 .998
DISCHARGE
URINE
ABNORMALITIES
29.467 3388.396 .000 1 .993 .000 .
MANAGEME .779 2.872 .073 1 .786 .008 606.993
Followup Haematuria Vs Presentation Haematuria
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Discharge Creatinine and urea were considered to be the risk
factors associated with proteinuria at 3 months.
Risk factors analysis for follow up Haematuria:
Follow-up Hematuria Vs Sex
Sex Yes No Total P Value
Male 15(26.3%) 42(73.7%) 57
Female 7(21.2%) 26(78.8%) 33 0.587
Total 22(22.4%) 68(78.6%) 90
Follow-up Hematuria Vs Presentation Proteinuria
Yes No Total P Value
Yes 13(27.7%) 34(72.3%) 47
No 9(20.9%) 34(79.1%) 43 0.458
Total 22(24.4%) 68(75.6%) 90
Follow-up Hematuria Vs Presentation Hematuria
Yes No Total P Value
Yes 11(21.2%) 41(78.8%) 52
No 1(2.6%) 37(97.4%) 38 0.011
Total 12(13.3%) 78(86.7%) 90
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Follow-up Hematuria Vs Presentation Urine Abnormalities
Yes No Total P Value
Yes 19 48 67
No 3 20 23 0.114
Total 22 68
Follow-up Hematuria Vs Management
Yes No Total P Value
Conservative 3 27 30
RRT 19 41 60 0.042
Total 22 68 90
Follow-up Hematuria Vs Discharge Urine abnormalities
Yes No Total P Value
Yes 19 28 47
No 3 40 43 0.001
Total 22 68 90
Follow-up Hematuria Vs Discharge GFR
GFR > 90 GFR ? 90 Total P Value
Yes 22 48 70
No 0 20 20 0.002
Total 22 68 90
46
Follow-up Hematuria Vs. Anemia
Yes No Total P Value
Yes 17 43 60
No 5 25 30 0.225
Total 22 68 90
Comparisons of Mean values for Hematuria at follow up:
Yes No P Value
Age 38.59±13.97 39.16±14.01 0.86
Hemoglobin 9.91±1.9 10.81±2.4 0.118
Presentation Sr.
Creatinine
5.159±2.61 5.404±3.07 0.738
Peak Sr.
Creatinine
8.8±3.19 6.83±3.02 0.11
Presentation
Urea
151.59±74.23 130.26±64.41 0.097
Peak Urea 179.95±58.27 155.26±60.13 0.095
Hemodialysis
from day of
detection
2.79±1.18 3.17±2.167 0.476
Discharge Sr.
Creatinine
3±0.98 1.83±0.985 0.001
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Multiple logistic regression analysis for Hematuria at follow up:
Observed Predicted
Hematuria
Percentage
Correct
Yes No
Step 1 Follow up
Hematuria
Yes
13 9 59.1
No 4 64 94.1
Overall Percentage 85.6
a  The cutoff value is .500
B S.E. Wald df Sig. 95.0% C.I.for EXP(B)
Lower Upper
AGE -.030 .029 1.086 1 .297 .918 1.027
SEX 1.686 .903 3.487 1 .062 .920 31.695
HB .009 .193 .002 1 .962 .691 1.474
PEAK CREATININE -.121 .224 .294 1 .588 .571 1.373
PRESENTATION
CREATININE
.598 .266 5.070 1 .024 1.081 3.061
PEAK  UREA .004 .018 .047 1 .828 .970 1.039
PRESENTATION UREA -.016 .015 1.229 1 .268 .956 1.013
PRESENTATION URINE
ABNORMALITIES
.065 1.056 .004 1 .951 .135 8.454
DISCHARGE
CREATININE
-1.020 .574 3.162 1 .075 .117 1.110
DISCHARGE UREA .002 .020 .007 1 .933 .963 1.042
DISCHARGE URINE
ABNORMALITIES
2.800 .969 8.354 1 .004 2.463 109.827
MANAGEME -.821 1.033 .632 1 .427 .058 3.332
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Presentation Sr.creatinine, discharge urinary abnormalities were
associated with the risk of hematuria at 3 months.
Risk factors analysis for follow up renal dysfunction:
Follow-up renal Dysfunction Vs Sex
Sex GFR > 90 GFR ? 90 Total P Value
Male 46(80.7%) 11(19.3%) 57
Female 25(75.8%) 8(24.2%) 33 0.580
Total 71(78.9%) 19(21.1%) 90
Follow-up Renal Dysfunction Vs Presentation Proteinuria
GFR > 90 GFR ? 90 Total P Value
Yes 37(78.7%) 10(21.3%) 47
No 34(79.1%) 9(20.9%) 43 0.968
Total 71(78.9%) 19(21.1%) 90
Follow-up Renal Dysfunction Vs Presentation Hematuria
GFR > 90 GFR ? 90 Total P Value
Yes 36(69.2%) 16(30.8%) 52
No 35(92.1%) 3(7.9%) 38 0.009
Total 71(78.9%) 19(21.1%) 90
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Follow-up Renal Dysfunction Vs Presentation Urine Abnormalities
GFR > 90 GFR ? 90 Total P Value
Yes 50 17 67
No 21 2 23 0.076
Total 71 19 90
Follow-up Renal Dysfunction Vs Management
GFR > 90 GFR ? 90 Total P Value
Conservative 28 2 30
RRT 43 17 60 0.031
Total 71 19 90
Follow-up Renal Dysfunction Vs Discharge Urine abnormalities
GFR > 90 GFR ? 90 Total P Value
Yes 30 17 47
No 41 2 43 0.001
Total 71 19 90
Follow-up Renal Dysfunction Vs Discharge GFR
GFR > 90 GFR ? 90 Total P Value
GFR > 90 20 0 20
GFR ? 90 51 19 70 0.004
Total 71 19 90
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Comparison of  Mean values with follow up Renal Dysfunction :
Yes No P Value
Age 38.08±14.21 42.53±12.52 0.219
Hemoglobin 10.81±2.44 9.78±1.72 0.09
Presentation Sr.
Creatinine
5.17±3.04 5.98±2.58 0.288
Peak Sr. Creatinine 6.95±3.19 8.66±2.75 0.035
Presentation Urea 129.37±63.98 158.32±75.32 0.095
Peak Urea 154.7±58.95 185.95±60.48 0.044
Hemodialysis from
day of detection
3.05±2.13 3.05±1.97 0.98
Discharge Sr.
Creatinine
1.78±0.76 3.38±1.25 0.001
Logistic regression analysis for follow up renal dysfunction:
Observed Predicted
Fol creat
Percentage
Correct
Normal Abnormal
Step 1 Follow up
creatinine
Normal
68 3 95.8
Abnormal 7 12 63.2
Overall Percentage 88.9
The cutoff value is .500
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Observed Predicted
Fol creat
Percentage
Correct
Normal Abnormal
Step 1 Fol creat Normal 67 4 94.4
Abnormal 3 16 84.2
Overall Percentage 92.2
a  The cut-off value is .500
B S.E. Wald df Sig.
95.0% C.I.for
EXP(B)
Lower Upper
AGE .079 .046 3.026 1 .082 .990 1.184
SEX -1.512 1.403 1.161 1 .281 .014 3.451
HB .496 .335 2.191 1 .139 .852 3.165
PEAK CREATININE -.304 .272 1.242 1 .265 .433 1.259
PRESENTATION
CREATININE
-.206 .341 .365 1 .546 .417 1.589
PEAK  UREA .021 .023 .857 1 .354 .976 1.069
PRESENTATION
UREA
-.014 .017 .716 1 .398 .954 1.019
PRESENTATION
URINE
ABNORMALITIES
2.158 1.684 1.642 1 .200 .319 234.763
DISCHARGE
CREATININE
3.445 1.238 7.746 1 .005 2.771 354.874
DISCHARGE UREA -.051 .032 2.577 1 .108 .892 1.011
DISCHARGE
URINE
ABNORMALITIES
-4.904 1.781 7.578 1 .006 .000 .244
MANAGEME 2.938 2.018 2.120 1 .145 .362 984.801
Discharge Sr.creatinine & Discharge urinary abnormalities were
associated with the renal dysfunction at follow up.
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Risk factors analysis of  Overall follow-up abnormalities:
Overall follow-up abnormalities vs Sex.
Sex Normal Abnormal Total P Value
Male 39 18 57
Female 21 12 33 0.643
Total 60 30 90
Overall follow-up abnormalities Vs Presentation Proteinuria.
Normal Abnormal Total P Value
Yes 0 12 12
No 60 18 78 .001
Total 60 20 92
Overall follow-up abnormalities Vs Presentation Haematuria
Normal Abnormal Total P Value
Yes 0 22 22
No 60 8 68 0.001
Total 60 30 90
Overall follow-up abnormalities Vs Presentation Urine
Abnormalities
Normal Abnormal Total P Value
Yes 20 3 23
No 40 27 67 0.013
Total 60 30 90
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Overall follow-up abnormalities Vs Management
Normal Abnormal Total P Value
Conservative 26 4 30
RRT 34 26 60 0.011
Total 60 30 90
Overall follow-up abnormalities Vs Discharge Urine abnormalities
Normal Abnormal Total P Value
Yes 39 4 43
No 21 26 47 0.001
Total 60 30 90
Overall follow-up abnormalities vs Old Age
Normal Abnormal Total P Value
Yes 44 19 63
No 16 11 27 0.329
Total 60 30 90
Overall follow-up abnormalities Vs. Anemia
Normal Abnormal Total P Value
Yes 36 24 60
No 24 6 30 0.058
Total 60 30 90
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Comparison of Mean variables for overall follow-up abnormalities:
Normal Abnormal P Value
Age 38.72±14.16 39.63±13.64 0.77
Hemoglobin 10.95±2.54 9.86±1.69 0.037
Presentation Sr.
Creatinine
6.618±2.97 8.707±3.2 0.003
Peak Sr.
Creatinine
6.95±3.1 8.66±2.7 0.035
Presentation
Urea
151.53±59.76 180.83±57.43 0.029
Peak Urea 154.7±58.95 185.95±60.48 0.44
Discharge Sr.
Creatinine
1.68±.73 2.98±1.20 0.001
Logistic regression analysis:
Observed Predicted
Fol overa
Percentage
Correct
Normal Abnormal
Step 1 Follow up
overall
Normal
57 3 95.0
Abnormal 7 23 76.7
Overall Percentage 88.9
a  The cutoff value is .500
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B S.E. Wald df Sig.
95.0% C.I.for
EXP(B)
Lower Upper
AGE .014 .025 .306 1 .580 .966 1.064
SEX -.527 .789 .446 1 .504 .126 2.771
HB .103 .198 .270 1 .603 .752 1.633
PEAK
CREATININE
-.049 .185 .071 1 .791 .662 1.369
PRESENTATION
CREATININE
-.161 .186 .745 1 .388 .591 1.227
PEAK  UREA .004 .015 .085 1 .770 .976 1.034
PRESENTATION
UREA
.005 .012 .159 1 .690 .981 1.030
PRESENTATION
URINE
ABNORMALITIES
1.326 1.187 1.249 1 .264 .368 38.572
DISCHARGE
CREATININE
2.009 .665 9.122 1 .003 2.024 27.461
DISCHARGE
UREA
-.026 .022 1.468 1 .226 .934 1.016
DISCHARGE
URINE
ABNORMALITIES
-3.103 .930 11.126 1 .001 .007 .278
MANAGEME .788 .917 .740 1 .390 .365 13.265
Discharge Sr.creatinine & Discharge urinary abnormalities were
associated with the risk of overall follow up abnormalities.
DISCUSSION
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DISCUSSION
This study was designed to know the characteristics and short
term (3 months) outcome of 96 AKI patients belonging to AKIN stage
III. In this study, other co-morbid illnesses like systemic hypertension,
Diabetes mellitus, previous renal illness, obstructive uropathy and
decompensated liver disease where excluded. This study was intended
on adult patients with the median age group in our study is 36 years,
representing mainly middle aged population. 30.2% of the patient were
in >50 years age group. The maximum age in this study was 66 years.
Since this study has more middle aged populations devoid of the above
mentioned co morbid illness, it has best characterized the outcome of
severe AKI. There was a nearly equal distribution of sex in this study
with male: female ratio was 1.6:1. This study included only the intrinsic
renal AKI(by FeNa) , since this group best characterize the outcome in
contrary to Pre renal and Post renal AKI. The Post renal AKI was
excluded in view of difficulty in accessing the duration of AKI and also
the pre existing renal abnormalities could not be ruled out.
At presentation, oliguria/ anuria, volume overload and anemia
was present in 70.88%, 23.95% and 66.66% respectively. The impact of
AKI on anemia could not be studied since most of the patients on
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admission were anemic. The peak Serum creatinine and Blood urea
were 7.2 mg/dl   and 162 mg/dl respectively indicating this study
population had severe renal failure and hence the renal outcome could
be better studied. Hyperkalemia was noted in 12.5% of the patients.
Hyperkalemia in AKI is due to reduced glomerular filtration rate,
decreased tubular secretion of potassium, tissue break down and
metabolic acidosis (65). Hyponatremia was the commonest abnormality
noted with 54.1% of AKI patients developing it .Hyponatremia occurs
mainly due to increased fluid retention and less commonly due to
sodium depletion (hypovolemia)(65). Urinary abnormalities like
Haematuria and/or proteinuria was identified in 70 patients (72.91%) on
admission. All the patients had FeNa >2, indicating intrinsic AKI.
Haematuria was defined as either dipstick positive or RBC > 2 / hpf in
unspun urine, while proteinuria was defined as spot urine PCR >0.3.
Only few patients with adequate urine output did have normal urinary
microscopy. 68% of the patients underwent renal replacement therapy.
Among them only one received acute peritoneal dialysis (PD. PD has
always been considered as inferior to hemodialysis in AKI (53) although
a study from Brazil showed that its efficiency is as equal to
hemodialysis in AKI (54).  The lone patients who underwent PD
recovered his renal function completely and regained normal renal
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function at 3 month follow-up. The most common indications for RRT
were volume overload (70%), uremic encephalopathy (20%) and
hyperkalemia (18%). None had uremic pericarditis. The mean number
of days of HD initiation from the detection of AKI was 3±2.29 days and
the mean number of HD sessions was 8±3.14 days. 34.37% received
conservative management. The mean age, sex, mean presenting and
peak Blood urea, mean presenting and peak Serum creatinine, Serum
sodium and potassium & mortality were comparable between the 2
groups. The discharge Serum creatinine were significant between the
groups, 2.32± 1.22 mg/dl in RRT group and 1.72±0.68 mg/dl in
conservative group (P=0.015).Mean Hemoglobin concentration
(p=0.005),presence of Oliguria/anuria(p=0.002),mean presenting
Creatinine(0.021),peak blood urea(0.001) vary significantly between the
groups. Mortality between two groups could not be compared because
all the three deaths in the conservative groups were out of multi organ
dysfunction and hypotension that precluded hemodialysis that time. The
mortality rate in AKI depends on the cause and the setting of the
occurrence of the AKI which varies between      20-70%, with sepsis
AKI in critical care units having 70% mortality (67,68,69). The lower
mortality rate in our series probably explains the fact that majority of the
patients had non critical care illness AKI. Discharge urine abnormalities
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were present in 60.83% of RRT group and 30.3% in conservative group
(p=0.018). At discharge renal dysfunction, defined as GFR < 90ml/min
as per Cockcroft- gault method was found in 77.77%. As per Schiffl et
al., 57% of the survivors of critically ill dialysis requiring AKI patients
regained normal renal function at discharge and none of the remaining
43% required RRT(70) . In contrary, our series had more patients with
renal dysfunction at discharge and 5 patients remained dialysis
dependent at discharge. Urinary abnormalities was present in 48.93% of
the patients, the mean serum creatinine at the time of discharge was
2.11±1.1 mg/dl. Another study looking at the AKI in critical ill patients
found that 4-18% of patients expired after discharge. In this study, only
one patient expired during the follow-up period.
The overall discharge abnormalities which included hematuria
and/or proteinuria and/or renal dysfunction were found in 87.77%.
Acute Tubular Necrosis (ATN) typically follows three phase like
initiation phase, maintenance phase, which lasts for 1.2 weeks and
recovery phase or diuretic phase. The expected recovery from ATN is
usually 3-4 weeks from its insult although conversion to acute cortical
necrosis makes the recovery unlikely. Although initial insult in ischemic
or nephrotoxic ATN occurs in the tubular epithelial cells, which
contributes to the initiation phase, it is the endothelial cell injury that
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contributes to the maintenance or oliguric phase. Also, the endothelial
injury triggers vasoconstriction, intra vascular coagulation causing
decrease in the density of interstitial capillaries termed as vascular
dropouts to the range of 30-50%(61). These vascular drop outs result in
persistent ischemia to the interstitium which eventually results in
interstitial fibrosis and hence progressive chronic kidney disease. AKI
can cause ESRD directly, increase the risk of developing CKD and also
worsens the underlying CKD. Severity, duration and frequency of AKI,
advanced age, presence of Diabetes mellitus, low baseline GFR, low
Sr.albumin   are considered to be the risk factors in the progression to
advanced CKD(71, 72). Our study is unique in the sense that urinary
abnormalities along with renal dysfunction were taken into
consideration for assessing renal damage. The patients who had either
proteinuria or Hematuria or renal dysfunction were subjected for renal
biopsy. The overall follow up abnormalities defined as the presence of
either Hematuria or proteinuria or renal dysfunction or abnormal renal
biopsy was present in 30 patients (33.33%). Renal dysfunction defined
as GFR<90ml/min was present in 18 patients (20%).
Isolated urinary abnormalities without renal dysfunction were
found in 16.66% of the patients. The follow-up renal biopsy was done in
19 out of  30 patients who fulfilled the criteria of renal biopsy among the
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left over 11 patients, 5 had dialysis dependent renal failure and other 2
had severe renal failure (GFR<30ml/min) with echogenic smaller
kidneys. Hence biopsy was deferred in these 7 patients. The remaining 4
patients refused for renal biopsy. Among them one had renal
dysfunction alone and other three had micro-hematuria alone. The
common histological abnormalities found were interstitial inflammation
in 6, interstitial fibrosis and tubular atrophy in 6, mesangial
proliferation, MPGN pattern in 1 each. All the patients who were overall
normal at discharge were found to be overall normal at 3 month follow
up. All the 6 normal biopsies were associated with isolated urinary
abnormalities. As far as the outcome of various histopathologies at
presentation are concerned, ATN had the best recovery with 19 out of
23 recovered completely not warranting  renal biopsy and only two had
abnormal renal biopsies at follow up. Acute interstitial nephritis (AIN)
with or without ATN had comparatively poor prognosis with 7/12
having abnormal biopsy and so as TMA (2/3) and Endocapillary
proliferative GN (2/3). As far as AIN is concerned, recent case series
showed 64% have full recovery and the remaining 36% have partial and
severe renal impairment (73).In this study 58.33% had abnormal renal
biopsy at 3 months follow up. Regarding the outcome of ATN, 43% had
renal failure at one year follow up as per Schiffl et al (74).In this study;
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only 9% were found to have renal damage at follow-up. The risk factor
analysis showed female sex (p=0.003), lower hemoglobin (p=0.002),
presentation Hematuria (p=0.011), discharge urine abnormalities
(p=0.001), peak blood urea (p=0.043) and discharge serum creatinine
(p=0.001) were significantly associated with proteinuria at 3months
follow up. Multi-variate analysis showed discharge serum creatinine and
urea were associated with the risk of proteinuria at 3 months. Risk factor
analysis of Hematuria at follow up showed presentation Hematuria
(p=0.011) RRT requiring (p=0.042), discharge urine abnormalities
(p=0.001), discharge GFR (p=0.002) and serum creatinine (p=0.001)
were significantly associated with this abnormalities. Multi-variate
analysis showed presentation serum creatinine, discharge urinary
abnormalities were associated with the risk of Haematuria at 3 months.
Presentation Haematuria (p=0.009) , RRT requiring (p=0.031),
discharge urine abnormalities (p=0.001), discharge serum creatinine
(p=0.001) and peak serum creatinine (p=0.0035) were associated with
renal dysfunction at 3 months. Discharge serum creatinine and discharge
urinary abnormalities were significantly associated with the risk of renal
dysfunction at 3 months. As far as the overall abnormalities at follow up
were concerned, this study showed presentation proteinuria (p=0.001),
Hematuria (p=0.001), presentation urine abnormalities (p=0.013),
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discharge urine abnormalities (p=0.001), presentation serum creatinine
(p=0.003), presentation urea (p=0.029), peak serum creatinine (p=0.003)
and discharge serum creatinine (p=0.001) were significantly associated
with that abnormality at 3 months .Multivariate analysis showed serum
creatinine and urinary abnormalities at discharge were associated with
the increased risk of overall renal abnormalities at 3 months. Many
studies including a study by Ishani et al showed magnitude of Serum
creatinine during the post operative period was linked with the
progression to CKD among the AKI survivors(75).This study showed
presentation, peak and discharge Serum creatinine were associated with
risk of renal damage at short term follow up.
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CONCLUSIONS
1.  Severe AKI (AKIN STAGE III) is common in the hospital
setting.
2.   The patients who receive RRT have significantly high risk of
having high Serum creatinine at discharge, persistent hematuria
and renal dysfunction at 3 months.
3.  More than two thirds of AKIN III AKI patients have evidence of
renal damage at discharge viz., proteinuria, hematuria and renal
dysfunction at discharge.
4.  Nearly one third of the survivors of severe AKI have evidence of
residual renal involvement at 3 months.
5.  The patients who have no evidence of residual renal involvement
at discharge continue to be the same at 3 months.
6.  The patients who are dialysis dependent at discharge continued to
be dialysis dependent and vice versa.
7.  All the patients who had persistent renal dysfunction have
abnormal renal biopsy at 3 months.
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8.  Acute tubular necrosis (ATN) has the best prognosis among all
the AKI histologies. Acute interstitial nephritis in isolation or in
combination with ATN has worse prognosis causing persistent
interstitial inflammation, fibrosis and tubular atrophy.
9.  Discharge urinary abnormalities, Presentation & Discharge Sr.
Creatinine are associated with persistent renal involvement at 3
months.
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ABBREVATION
TGF – Transforming Growth Factor
IFN-? – Interferon ?
GLDH – Glutamide Lactate Dehydrogenase
GOD-PAP – Glucose Oxidase Dehydrogenase, Glucose Peroxidase
Dehydrogenase
IFCC – International Federation of Clinical Chemistry
BCG – Bromo Cresol Green
TNF – Tumor Necrosis Factor
IL – Inter Leukin
VEGF – Vascular Endothelial Growth Factor
MCP – Membrane Cofactor Protein
AKIN – Acute Kidney Injury Network
KIM – Kidney Injury Molecule
NGAL – Neutrophil Gelatinase Associated Lipocalin
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ANNEXURES
PROFORMA
 N.c no:
Name: Age/Sex:    IP.No:
Address: Ph.No:
Occupation:
 D.O.A:       D.O.D:
Clinical History/ Finding:
Volume Overload:  (JVP// Pedal Edema// Lungs Sings)
Fever:                                       Drugs:
Hematuria:
ADD:                                                 Native medicines:
Encephalopathy:
Jaundice:           DCLD
Pericarditis:
Snake bite/ Obstretic:
Rashes:
Insect sting
Post operative: Radio Contrast:
Arthritis:
Hypotension:          Hypertension:
Others:
Cardiac dysfucntion:                      Oliguria:
Date
Hb
TC
DC
Platelets
RBS
Bld.Urea
Sr.Creatinine
Sr.Sodium
 Sr..Potassium
Sr.Calcium
Sr.Phosphorus
Sr.Uric acid
Sr.bilurubin
Sr.SGOT
Sr.SGPT
Sr.Alk Phos
Urine
Routine
24 Hr Protein
FeNA
Viral Markers
C3 C4
ANA
ASO
ANCA
MSAT(Lepto)
MP
Cultures
Study
Other Studies
Urine Output
USG Abdomen:  X- ray KUB:
X-ray Chest:
Renal Biopsy :
ECG:
Diagnosis :
Management:             Conservative// Hemodialysis//Peritoneal
Dialysis
              Day from detection of ARF:
                                                              No. of  HD// Cycles Of PD:
Outcome:
Alive/ Death
On Discharge:
Urea                         Creatinine                    Urine Routine
Follow-Up ( 3  Months)
Urea                          Creatinine 24 Hr Urine Protein
Urine Routine:
Sr. Creatinine Urea Proteinuri
a
hematuria Renal
Biopsy
Hospital Follow up
1 Renuga 22 F
Heavy metal
investigation Yes Yes - 8.1 14.5 14.5 182 182 134 5.86 Yes Yes ATN H 2 5 2 62 Yes Yes 1.2 37 Nil Nil - No No
2 Sekar 52 M
NSAIDS / LVD /
fever No No - 11.9 6.3 6.3 143 143 133 4.3 No Yes - C - - 3.2 90 No Yes 1.4 35 Nil yes - No No
3 Abilash 23 M Fever / ADD Yes Yes - 10.8 11.1 11.1 207 207 134.9 3.94 No Yes ATN H 7 3 1.5 48 No yes 1 20 Nil Nil - No No
4 Parimala 14 F ADD Yes No E, HO 12.5 8.5 2.8 188 42 129 3.89 Yes No - H 4 8 1.3 45 No No 1 19 Neg No - No No
5 Amudha 49 F Sepsis No Yes - 9.7 10 8.5 171 165 143 4.86 Yes Yes ATN H 2 5 1.8 38 No Yes 0.9 25 Nil Nil - No No
6 Rani 60 F NSAIDS No No HN 10.3 4 3.2 80 78 137 6.7 No No - C - - 1 42 Yes No 1 32 Nil Nil - No No
7 Ravi 49 M Malaria Yes Yes E,HN 13.5 9 9 231 231 143 5.37 No No - H 2 14 5 130 No No 2.7 50 No yes CIN No No
8 packson 36 M ADD Yes No - 14.3 5.6 5.6 130 130 139 4.2 No No - C - - 2.4 70 No No 0.9 26 No No - No No
9 Kovendhan 26 M Sepsis Yes Yes - 9.7 13.8 3 170 60 139 4.6 Yes Yes ATI H 3 22 2.6 73 Yes Yes 1.4 50 Nil yes - No No
10 Murugan 33 M ADD Yes No - 15.5 3.6 3.6 78 78 135 2.5 No No - C - - 1.4 69 Yes Yes 1 32 Nil Nil - No No
11 Selva Kumar 58 M Fever Yes Yes - 10.2 6.9 6.9 150 150 123 5.5 No No - H 7 2 1 20 No No 1 22 No No - No No
12 Raji 35 M ADD No No - 14 10.9 3.2 192 131 123 4.1 Yes Yes - C - - 2.7 48 No No 1 36 No No - No No
13 Ramu 20 M Cellulitis/ sepsis Yes No - 10.6 5.8 5.8 168 168 116 2.46 Yes No - C - - 1.5 38 No No 1 22 No No - No No
14 Govindammal 60 F ADD No No - 11.2 4.4 1.7 98 58 125 2.7 No Yes - C - - 2.8 68 No No 1 28 Nil Nil - No No
15 Manimegalai 52 F ADD No Yes - 9.6 10.1 10.1 252 252 130 4.5 No Yes AIN H 5 4 3.6 100 yes Yes 1 30 Yes Nil Y No No
16 Gandhi 44 M Malaria No No - 8.9 4.6 4.6 110 100 138.6 4.67 Neg Yes - C - - 2 40 No No 1 28 Neg Nil - No No
17 Rajeswari 66 F ADD Yes Yes - 7.7 8.5 4 166 68 137 2.1 Yes Yes - H 4 8 1.7 52 No Yes 0.9 30 Neg Neg - No No
18 Murugan 33 M ADD Yes - - 15.5 3.6 3.6 78 78 135 2.5 No No - C - - 1.4 69 No No 1 28 No No - No No
19 Kovendhan 26 M Fever Yes Yes 9.7 13.6 3 170 170 137 3.8 Yes Yes ATN H 3 22 2.6 73 Yes Yes 1.4 50 No Yes - No No
20 Sathish 19 M sepsis Yes Yes - 10.3 7.3 6.3 167 167 121 3.9 No Yes - H 2 4 1.2 47 Yes Yes 1 29 Nil Nil - No No
21 Esther 50 F NSAIDS Yes Yes - 9.1 8.7 7.1 301 301 118 5.5 No Yes AIN H 5 4 3.9 100 Yes Yes 3.4 100 Yes Yes
Chronic
interstitial
Nephritis,
Internal
No No
22 Jeyaraj 25 M Malaria Yes Yes E, HY, J 7.9 11.9 5 209 195 133 3.7 Yes Yes AIN / ATN H 2 15 3 88 Yes Yes 1.1 30 No Yes Normal No No
23 Santhanam 54 M ADD No No 10.8 9.8 9 226 173 133 5.5 Yes No - H 4 5 2.4 35 No No 1 28 No No - No No
24 Arumugam 40 M Pancreatitis Yes No J 7.3 10.1 10.1 359 359 116 3.42 Yes No - C - - 2 69 No No 1 30 No No - No No
25 Anand 49 M Leptospirosis Yes Yes HY 7.8 5 4.5 130 121 138 4 Yes Yes - H 2 5 1.8 48 Yes Yes 1.2 32 No No - No No
26 Ponnuswamy 40 M  sepsis Yes No - 11.4 11.7 6.4 182 140 137 4.4 Yes No - H 2 3 1.2 40 No Yes 1 30 No No - No No
27 Saranya 22 F post partum Yes Yes J 6.5 6.2 4 126 88 137 3.13 Yes Yes
TMA, Patcly cortical
Necrosis H 2 9.8 4 98 Yes Yes 5 100 Yes Yes CKD No No
28
Sundharamoorth
y 35 M ADD No No - 11 5.2 5.2 212 212 138 3.8 Yes No - C - - 1.3 32 No No 1 28 No No - No No
29 Shankar 40 M Sepsis Yes No - 9.9 2.7 2.6 141 132 135 3.6 No No - H 1 1 - - - - - - - - - - -
30 Kamalakannan 52 M
Sepsis /cardiac
failure Yes Yes - 8.2 6.1 2.2 146 71 127 3 No Yes - H 2 4 3.5 145 No No 0.9 29 No No - - -
31 Kumar 23 M NSAIDS No No HY 12.3 4.5 4.5 176 128 128 3.3 Yes Yes ATN H 2 3 1.1 28 Nil No 1 28 No No - No -
32 Perumal 48 M Multiple myeloma No No - 8.5 10.8 10.8 186 186 128.4 6.99 Yes Yes Cast Nephropathy ,
ATN
H 3 10 4.8 116 Yes Yes 8.4 123 Yes Yes
intertitial
fibrosis /
tubular
atrophy
No No
33 Arumugam 55 M pyelonephritis Yes Yes 8.9 7.5 5.9 158 136 116 3.5 Yes No - H 6 3 2.9 49 Nil Nil 1 30 No No - No No
34 Karunakaran 53 M sepsis Yes No E 9 4.8 4.8 262 262 124 7.4 No No - H 1 1 - - - - - - - - - Death -
35 Nagarathinam 36 M acute pancreatitis Yes Yes J 17.5 4.8 4.1 188 125 130 5.2 No No - H 3 7 1.9 60 Nil No 1 29 No No - - -
36 Ravi 52 M PIGN No No - 13.5 4.1 3.6 86 86 136 4.5 Yes Yes endo capillary
proliferation
C - - 2.4 80 Yes Yes 1 30 No Yes
mesangial
proliferatio
n, no
interstitial
inflammatio
n
- -
37 Jeyanthi 36 F
Post operative/
sepsis No Yes - 9.4 4.7 4.7 102 102 133 3.25 Yes Yes ATN H 1 3 1 28 No No 1 28 No No - -
38 Hussain 26 M fever No No HY 10 5.3 5.3 130 130 138 3.6 Yes Yes ATN C - - 1.1 30 Yes Yes 1 29 Yes No Normal - -
39 Vasanthi 40 F sepsis Yes No HO, E 9.8 4.4 2.7 110 120 138 4 No No - C - - - - - - - - - - - Death -
40 Prakash gosh 35 M ADD Yes No E 10.4 4.8 4.8 102 102 137 4 No No ATN H 2 5 5.2 120 No No - - - - - - No Follow up
41 Pattammal 50 F ADD Yes No 10 3.7 2.4 116 116 145 2.34 No No - C - - 1.3 40 No No 1 27 No No - - -
42 Krishnan 45 M ADD Yes No HO 17.4 3.1 3.1 160 160 136 4.9 No No - C - - 2.3 72 No No 1 28 No No - - -
43 Rajesh 17 M ADD No No #VALUE! 11.6 10.7 2.7 178 96 131 2.6 Yes No ATN H 7 2 1.6 40 No No 0.9 30 No No - - -
44 Krishnan 60 M Leptospirosis Yes No HY 10.4 8.7 8.5 178 127 122 4.4 Yes No ATI/ATN H 2 4 1.4 34 Yes No 1.3 40 No No
tubulo
intertitial
inflamation
focal
fibrosis
- -
45 Sathish kumar 23 M Pancreatitis Yes No E, HY 10.6 4.6 1.5 110 37 130 3.9 No No ATN H 2 2 1.4 36 No Yes 1.2 38 Yes Yes Normal - -
46 Gunasundari 22 F post partum/ sepsis Yes Yes HO 15.1 5.9 3.4 104 95 136 3.3 Yes No ATN H 2 9 1.3 32 No No 1 30 No No - - -
47 Zabana 30 F
post operative/
sepsis Yes Yes HY 10.1 4.7 7.2 140 94 134.1 3.07 Yes Yes ATN C - - 1.5 25 Yes Yes 0.9 28 No No - - -
48 Radha 46 F cardiac failure Yes Yes HO 12.1 2.6 2.6 96 96 136 4 No No - C - - - - - - - - - - - Death -
49 Ramesh Kumar 35 M Leptospirosis Yes Yes E, H, J 10.2 7 6 190 148 140 3.8 Yes Yes ATN PD 11 60 cycles 1.5 40 No No 1 26 No No - - -
50 Senthil 30 M Leptospirosis Yes Yes - 11 7.6 7.6 142 142 137 4.2 No No ATN H 1 5 2.8 57 No No 1 28 No No - - -
51 Poovarasan 34 M ADD / Cocaine No Yes HY, E 9.4 15.6 15.6 285 285 139 4.2 No No - H 1 3 1.4 30 No No 0.9 30 No No - - -
52 Ellappan 25 M acute pancreatitis No No J 11.2 3.5 3.5 113 94 134 3.5 No No - C - - 1.2 53 No No 1 28 No No - - -
53 Jeyanthi 36 F sepsis Yes Yes - 9.4 4.7 4.7 102 102 133 3.25 Yes No ATN H 3 3 1 35 No Yes 1 30 No No - - -
54 Saraswathy 57 F sepsis Yes Yes E 9 7.2 1.1 180 41 132 4.3 No Yes - C - - 1.7 40 No No 1 28 No No - - -
55 Rani 60 F NSAIDS No No - 10.3 2.1 2.1 45 45 137 3.3 No 2+ - C - - 1 38 No No 1 29 No No - - -
56 Vijayalakshmi 19 F Post patrum Yes Yes - 6.8 4 1.1 60 60 133 3.4 No No ATN H 2 3 1.2 28 No No 1.1 30 No No - - -
57 Ravi 52 M fever No No 13.5 4.1 3.6 86 86 137.8 3.92 Yes Yes - C - - 1 30 No No 1 34 No No - - -
58 Hussain 26 M fever No No - 13 9.3 5.3 88 50 142 3.2 No No - C - - 1 38 No No 1 30 No No - - -
59 Dalim 32 M
Post operative/
sepsis Yes Yes E 10.4 7.9 4.5 148 99 130 3.5 Yes No - H 2 8 2.4 82 Yes Yes 1 34 No No - - -
Urine ProtienDischarge
Creatinine
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overloaded
60 Ganesan 52 M fever Yes - - 8.7 4 4 171 118 123.4 3.24 No No - C - - 1.3 28 No No 0.9 30 No No - - -
61 Sathish kumar 25 M ADD Yes Yes - 15 6.2 2.9 187 56 127 3.5 No Yes ATN H 4 2 1.2 28 No No 1 29 No No - - -
62 Shiva 37 F PIGN Yes Yes HY 10.6 6.1 6.4 124 124 138.4 5 Yes Yes
endo capillary
proliferation with
exudation
H 3 6 4.5 140 Yes Yes 6.1 140 Yes - MPGN No No
63 Jeyalakshmi 16 F PIGN Yes No HY 12.4 3.4 2.5 120 110 136 4 Yes Yes
exudative
proliferation, GN C - - 1.2 30 Yes Yes 1 40 No - - - -
64 Khatum Bee 58 F NSAIDS/ fever Yes Yes E 10 6.4 5.8 130 124 126 3.8 Yes Yes ATN H 1 4 1.4 40 No No 1.1 36 No No - No No
65 Nagavalli 54 F fever Yes Yes HY 12 4.7 1.6 120 100 130 3.9 Yes Yes ATN / AIN H 2 3 1.4 38 No No 1 34 No Yes
focal
interstitial
infiltrates
- -
66 Sheriff 45 M acute pancreatitis Yes No - 11 4.5 3 110 104 135 3.8 Yes Yes AIN H 2 4 1.3 40 No No 1.4 36 No No - No No
67 Kumar 35 M acute pancrreatitis Yes Yes - 10.6 6.7 5.2 112 102 130 3.4 No Yes AIN H 3 6 2.2 48 No Yes 1.2 28 no Yes Normal No No
68 Jeyakumar 36 M
obstructive
uropathy/b/l
ureteric calculi
Yes Yes HY 13.4 8.2 6 140 110 140 3.9 No Yes - H 2 3 1.4 38 No Yes 1.1 30 No No - - -
69 Rajesh 28 M acute pancreatitis Yes Yes - 9.2 8 3.4 222 104 144 4.8 No Yes ATN/AIN H 2 2 - - - - - - - - - Death -
70 Savithri 50 F ADD No No - 10.4 3.4 2.6 140 100 128 4 No No - C - - 1 28 No Nil 0.9 38 No No - - -
71 Zahidha 48 F
AGN/ANCA
Vasculitis Yes Yes HY 8.6 8.8 3.4 240 122 134 3.8 Yes Yes crescentic GN H 3 14 6 80 Yes Yes - - - - - - death
72 Sivagami 60 F
AGN/ANCA
Vasculitis Yes Yes HY 10.4 7.4 4.6 220 184 140 4 Yes Yes crescentic GN H 2 8 - 74 Yes Yes 1.8 40 Yes Yes - - -
73 Thavamani 58 F AGN/PIGN Yes Yes - 9.8 8.4 4.2 210 100 144 5.6 Yes Yes crescentic GN H 2 10 - - - yes - - - - - Death -
74 Mariappan 16 M Leptospirosis Yes Yes HY 8.4 4.4 3.2 112 90 148 4.9 Yes Yes - C - - - - - - - - - - - Death -
75 Lakshmi 22 F Post partum/ sepsis Yes Yes - 10 6.5 2.4 200 100 131 3.8 Yes Yes
patchy acute cortical
necrosis H 1 16 2.4 86 Yes Yes 1.2 40 Yes Yes - -
76 Rekha 22 F Post partum/ sepsis Yes Yes - 8.1 14 14 180 180 134 5.86 Yes Yes ATN H 2 5 2 70 Yes Yes 1.2 36 No No
1nterstitial
fibrosis,
patchy
cortical
necrosis
- -
77 Shankar 52 M ADD No No - 11.9 6.3 6.3 142 142 133 4.3 No Yes - C - - 3.2 86 No Yes 1.4 30 No 2+ - - -
78 Parveen 15 F sepsis Yes No E,HO 12.5 8.5 2.8 207 207 134.9 3.94 No Yes ATN H 7 3 1.4 72 No yes 1 20 No No - - -
79 Aruna 49 F fever No Yes - 9.7 10 8.5 171 165 143 4.86 Yes Yes ATN H 2 5 1.8 60 No Yes 1 19 Neg Neg - - -
80 Veni 59 F ADD No No HN - 4 3.2 80 78 137 6.7 No No - C - - 1 42 Yes Nil 1 32 Neg Neg - - -
81 Raghu 49 M malaria Yes Yes E,HN 8.6 9 9 231 231 143 5.37 No No ATN / AIN H 2 14 2.6 22 Yes No 2.7 50 No Yes
Chronic
interstitial
Nephritis,
- -
82 Johnson 35 M ADD Yes No - 14.3 5.6 5.6 130 150 139 4.2 No No - C - - 2.4 46 No No 0.9 26 No No - - -
83 Ganesh 33 M sepsis Yes No - 15.5 3.6 3.6 78 78 135 2.5 No No - C - - 1.4 38 Yes Yes 1 32 No No - - -
84 Kannan 27 M sepsis Yes No - 9.7 13.8 3 170 60 139 4.6 No Yes ATI H 3 22 2.6 48 Yes Yes 1.4 50 Nil 3+ - - -
85 Megala 50 F ADD No No - 9.6 10.1 10.1 252 252 130 4.5 No Yes AIN H 5 4 3.6 69 yes Yes 1 30 Yes Nil Normal No No
86 Kandhan 44 M malaria No No - 8.9 4.6 4.6 110 100 138.6 4.67 Neg Yes - C - - 2 20 No Neg 1 28 Neg Nil - No No
87 Mageshwari 66 F fever Yes Yes - 7.7 8.5 4 166 68 137 2.1 Yes Yes - H 4 8 1.7 48 No Yes 0.9 30 Neg Neg - No No
88 Kavinraj 26 M fever Yes Yes H 9.7 13.6 3 170 170 137 3.8 Yes Yes AIN H 5 4 3.6 38 Yes Yes 1.4 50 No Yes - No No
89 Suresh 19 M ADD Yes Yes - 10.3 7.3 6.3 167 167 121 3.9 No Yes - H 2 4 1.2 68 Yes Yes 1 29 No No - No No
90 Mary 50 F fever Yes Yes - 9.1 8.7 7.1 301 301 118 5.5 No Yes AIN H 5 4 3.9 100 Yes Yes 3.4 100 Yes Yes
Chronic
Nephritis,
Intertitial
fibrosis
No No
91 Reganraj 25 M malaria Yes Yes E,HY,J 7.9 11.9 5 209 195 133 3.7 Yes Yes ATN / AIN H 2 15 3 40 Yes Yes 1.1 30 No Yes Normal No No
92 Sambandam 54 M ADD No No - 10.8 9.8 9 226 173 133 5.5 Yes No - H 4 5 2.4 52 No No 1 28 No Yes - No No
93 Ramalingam 40 M Pancreatitis No No J 7.3 10.1 10.1 359 359 116 3.42 Yes No - C - - 2 69 No No 1 30 No No - No No
94 Senthil 49 M leptospirosis Yes Yes HY 7.8 5 4.5 130 121 138 4 Yes Yes - H 2 5 1.8 73 No No 1 30 No No - No No
95 Mayil samy 40 M sepsis Yes No - 11.4 11 6.4 182 140 138 4 Yes No - H 2 3 1.2 47 No Yes 1 30 No No - No No
96 Suganya 22 F postpartum Yes Yes J 6.5 6.2 4 126 80 137 3.1 Yes Yes TMA, Patcly cortical
Necrosis
H 2 98 4 100 Yes Yes 5 100 Yes Yes
interstitial
fibrosis,glo
bal
glomerular
sclerosis
No No

